Skip to main content
Clinical Trials/NCT02716870
NCT02716870UnknownNot Applicable

Effect of Important Food Sources of Fructose-containing Sugars on Cardiometabolic Risk Factors: A Series of Systematic Reviews and Meta-analyses of Controlled Trials to Inform Dietary Guidelines, Public Health Policy, and Future Trial Design

University of Toronto1 site in 1 country1 target enrollmentStarted: June 2015Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Enrollment
1
Locations
1
Primary Endpoint
Inflammation

Study Overview

Brief Summary

Fructose-containing sugars have been implicated in the epidemics of obesity, diabetes and related cardiometabolic disorders. This view is supported by lower quality evidence from ecological observations, animal models, and select human trials. Higher level evidence from controlled trials and prospective cohort studies have been inconclusive. Whether sugars contribute to cardiometabolic complications independent of their calories remains unclear. To address the uncertainties, the investigators propose to conduct a series of systematic reviews and meta-analyses of the totality of the evidence from controlled trials to distinguish the contribution of fructose-containing sugars from that of energy in the development of markers of cardiometabolic risk. The findings generated by this proposed knowledge synthesis will help improve the health of consumers through informing evidence-based guidelines and improving health outcomes by educating healthcare providers and patients, stimulating industry innovation, and guiding future research design.

Detailed Description

Background: Sugars have emerged as one of the most important public health concerns. Attention has focused particularly on fructose-containing sugars (fructose, sucrose, high fructose corn syrup, honey, etc), which collectively have been indicted as drivers of various cardiometabolic complications. This special view rests on the unique metabolic and endocrine responses to fructose. Unlike glucose, fructose is thought to bypasses negative feedback controls acting as an unregulated substrate for de novo lipogenesis and impair satiety signaling resulting in weight gain. In support of these mechanisms, animal models, low-quality ecological studies, and select human trials of overfeeding at levels of exposure far beyond population intakes have reported adverse metabolic effects of sugars. Higher level evidence from systematic reviews and meta-analyses of controlled trials, however, suggests that any effects of sugars are mediated by excess calories rather than the sugars per se. It remains unclear whether fructose-containing sugars contribute to cardiometabolic complications independent of their calories.

Need for proposed research: High quality systematic reviews and meta-analyses of controlled trials represent the highest level of evidence to support dietary guidelines and public health policy development. As dietary guidelines and public health policy have shifted toward food and dietary-pattern based recommendations, there is an urgent need for systematic reviews and meta-analyses comparing the role of different food sources of sugars in the development of cardiometabolic diseases.

Objective: The investigators will conduct a series systematic reviews and meta-analyses to distinguish the effect of fructose-containing sugars from that of energy on measures of cardiometabolic risk in controlled trials.

Design: Each systematic review and meta-analysis will be conducted according to the Cochrane Handbook for Systematic Reviews of Interventions and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).

Data sources: MEDLINE, EMBASE, and The Cochrane Central Register of Controlled Trials (Clinical Trials; CENTRAL) will be searched using appropriate search terms supplemented by hand searches of references of included studies.

Study Design

Study Type
Observational
Observational Model
Other
Time Perspective
Other

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Trials in humans
  • Oral fructose-containing sugars intervention
  • Presence of an adequate comparator (substitution, addition, subtraction, or ad libitum control)
  • Diet duration >=7 days
  • Viable outcome data

Exclusion Criteria

  • Non-human trials
  • Observational studies
  • IV or parenteral fructose-containing sugars
  • Lack of suitable comparator (i.e. a comparator arm that contains substantial fructose-containing sugars)
  • Diet duration <7 days
  • No viable outcome data

Outcomes

Primary Outcomes

Inflammation

Time Frame: Up to 20 years

c-reactive protein (CRP)

Glycemic Control

Time Frame: Up to 20 years

glycated blood proteins, fasting blood glucose, fasting blood insulin

Established Therapeutic Blood Lipid Targets

Time Frame: Up to 20 years

LDL-cholesterol, apol B, non-HDL-cholesterol, HDL-cholesterol, triglycerides

Blood Pressure

Time Frame: Up to 20 years

Uric Acid

Time Frame: Up to 20 years

Blood uric acid concentrtaions

Non-Alcoholic Fatty Liver Disease (NAFLD)

Time Frame: Up to 20 years

Intrahepatocellular lipid concentrations (IHCL), ALT

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

John Sievenpiper

Associate Professor

University of Toronto

Study Sites (1)

Loading locations...

Similar Trials